Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance

Receptor tyrosine kinases are a diverse family of transmembrane proteins that can activate multiple pathways upon ligation of the receptor, one of which is the series of mitogen-activated protein kinase (MAPK) signaling cascades. The MAPK pathways play critical roles in a wide variety of cancer type...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research 2013-05, Vol.19 (9), p.2301-2309
Main Authors:	PRITCHARD, Antonia L, HAYWARD, Nicholas K
Format:	Article
Language:	eng
Subjects:	Antineoplastic agents Antineoplastic Agents - pharmacology Biological and medical sciences Clinical Trials as Topic Drug Resistance, Neoplasm - genetics Humans MAP Kinase Signaling System Medical sciences Melanoma - drug therapy Melanoma - enzymology Melanoma - genetics Mitogen-Activated Protein Kinases - genetics Mutation Pharmacology. Drug treatments Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Receptor tyrosine kinases are a diverse family of transmembrane proteins that can activate multiple pathways upon ligation of the receptor, one of which is the series of mitogen-activated protein kinase (MAPK) signaling cascades. The MAPK pathways play critical roles in a wide variety of cancer types, from hematologic malignancies to solid tumors. Aberrations include altered expression levels and activation states of pathway components, which can sometimes be attributable to mutations in individual members. The V600E mutation of BRAF was initially described in 2002 and has been found at particularly high frequency in melanoma and certain subtypes of colorectal cancer. In the relatively short time since this discovery, a family of drugs has been developed that specifically target this mutated BRAF isoform, which, after results from phase I/II and III clinical trials, was granted U.S. Food and Drug Administration approval in August 2011. Although these drugs produce clinically meaningful increases in progression-free and overall survival, due to acquired resistance they have not improved mortality rates. New drugs targeting other members of the MAPK pathways are in clinical trials or advanced stages of development. It is hoped that combination therapies of these new drugs in conjunction with BRAF inhibitors will counteract the mechanisms of resistance and provide cures. The clinical implementation of next-generation sequencing is leading to a greater understanding of the genetic architecture of tumors, along with acquired mechanisms of drug resistance, which will guide the development of tumor-specific inhibitors and combination therapies in the future.
ISSN:	1078-0432 1557-3265